The Growing Need for STI and Antimicrobial Resistance Detection
The global prevalence of sexually transmitted infections (STIs) exceeds 1 million new cases daily, with the majority being asymptomatic. Annually, this totals around 374 million new infections, encompassing common curable STIs such as chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium (MG). In addition to these, the detection of NG fluoroquinolone resistance markers and MG macrolide and fluoroquinolone resistance markers is crucial. These infections and resistance markers can lead to complications such as cervicitis, urethritis, preterm labor, pelvic inflammatory disease (PID), and heightened vulnerability to HIV. Consequently, accurate detection of these prevalent STIs and resistance markers is crucial for clinical researchers to monitor outbreaks, track resistance trends, and guide treatment strategies.
